(Q35741552)

10 August 2017

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer (English)

1 reference

10 August 2017

1 reference

Michael J Shulman

1

1 reference

10 August 2017

Jose A Karam

series ordinal

2

1 reference

10 August 2017

Elie A Benaim

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

10 August 2017

1 reference

10 August 2017

63

1 reference

10 August 2017

4

1 reference

10 August 2017

732-736

1 reference

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Hormone-refractory (D3) prostate cancer: refining the concept.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Natural history of progression after PSA elevation following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.11.016

10.1016/J.UROLOGY.2003.11.016

7 January 2021

Identifiers

DOI

1 reference

10 August 2017

1 reference